Keynote Conference
Samuel Yamshon, MDWeill Cornell Medicine/NewYork-Presbyterian
Thomas Marron, MD, PhDThe Tisch Cancer Institute at Mount Sinai
Medical Spotlight
Rahul Banerjee, MD, FACPFred Hutchinson Cancer Center
Sam Brondfield, MD, MAUCSF Helen Diller FamilyComprehensive Cancer Center
Jennifer Effie Amengual, MDColumbia University Hebert IrvingComprehensive Cancer Center
Danielle E. Hammond, MD, FRCP(C)The University of TexasMD Anderson Cancer Center
Amanda Nizam, MDCleveland Clinic
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer
Ipatasertib/Anti-HER2 Therapy Is Safe and Active in PIK3CA-Mutant, HER2+ Advanced Breast Cancer
Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer